PriceTargets.com logo

Guardion Health Sciences - GHSI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.22 As of 10/30/2024 10:06 PM ET
▼ -0.07 (-2.13%)

This chart shows the closing price for GHSI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardion Health Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GHSI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GHSI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Guardion Health Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.22.

This chart shows the closing price for GHSI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Guardion Health Sciences. This rating has held steady since June 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/2/2024Maxim GroupReiterated RatingBuy ➝ Hold
7/18/2022Ascendiant Capital MarketsInitiated CoverageBuy$37.50
5/13/2022Maxim GroupReiterated RatingBuy$30.00
3/8/2022Maxim GroupInitiated CoverageBuy$30.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Guardion Health Sciences logo
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Read More

Today's Range

Now: $3.22
Low: $3.22
High: $3.29

50 Day Range

MA: $4.66
Low: $3.22
High: $10.93

52 Week Range

Now: $3.22
Low: $3.04
High: $18.00

Volume

4,700 shs

Average Volume

105,261 shs

Market Capitalization

$4.35 million

P/E Ratio

0.66

Dividend Yield

155.28%

Beta

0.73

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardion Health Sciences?

The following Wall Street research analysts have issued stock ratings on Guardion Health Sciences in the last year: Maxim Group.
View the latest analyst ratings for GHSI.

What is the current price target for Guardion Health Sciences?

0 Wall Street analysts have set twelve-month price targets for Guardion Health Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Guardion Health Sciences in the next year.
View the latest price targets for GHSI.

What is the current consensus analyst rating for Guardion Health Sciences?

Guardion Health Sciences currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GHSI, but not buy more shares or sell existing shares.
View the latest ratings for GHSI.

What other companies compete with Guardion Health Sciences?

Other companies that are similar to Guardion Health Sciences include Hepion Pharmaceuticals, Imunon, Marinus Pharmaceuticals, Synlogic and Cara Therapeutics. Learn More about companies similar to Guardion Health Sciences.

How do I contact Guardion Health Sciences' investor relations team?

Guardion Health Sciences' physical mailing address is 15150 AVENUE OF SCIENCE SUITE 200, SAN DIEGO CA, 92128. The company's listed phone number is (800) 873-5141 and its investor relations email address is [email protected]. The official website for Guardion Health Sciences is www.guardionhealth.com. Learn More about contacing Guardion Health Sciences investor relations.